Clinical Trials Browser

INDUSTRY × Carcinoma, Non-Small-Cell Lung × sapanisertib × Clear all

NCT05275673 2025-04-24

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Phase 2 Terminated

7 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence